Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-8.14 Insider Own0.50% Shs Outstand111.35M Perf Week1.55%
Market Cap11.78B Forward P/E- EPS next Y-4.69 Insider Trans-41.73% Shs Float111.35M Perf Month-9.49%
Income-886.10M PEG- EPS next Q-1.88 Inst Own95.10% Short Float4.36% Perf Quarter-8.52%
Sales219.80M P/S53.61 EPS this Y-7.00% Inst Trans0.27% Short Ratio6.16 Perf Half Y37.97%
Book/sh12.87 P/B8.22 EPS next Y33.90% ROA-36.70% Target Price141.45 Perf Year15.71%
Cash/sh13.80 P/C7.67 EPS next 5Y46.09% ROE-55.80% 52W Range65.81 - 134.51 Perf YTD-8.12%
Dividend- P/FCF- EPS past 5Y-10.80% ROI-65.40% 52W High-21.33% Beta1.94
Dividend %- Quick Ratio4.70 Sales past 5Y34.20% Gross Margin88.60% 52W Low60.80% ATR9.45
Employees1323 Current Ratio4.90 Sales Q/Q241.40% Oper. Margin- RSI (14)48.09 Volatility6.47% 11.15%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.10% Profit Margin- Rel Volume0.63 Prev Close104.21
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume788.43K Price105.82
Recom2.00 SMA201.76% SMA50-7.61% SMA2009.18% Volume496,443 Change1.54%
Mar-19-20Initiated Berenberg Buy $200
Dec-19-19Reiterated Chardan Capital Markets Buy $150 → $190
Nov-20-19Initiated Oppenheimer Outperform $128
Nov-13-19Initiated BofA/Merrill Buy $110
May-23-19Resumed Goldman Neutral $80
Apr-12-19Initiated Evercore ISI Outperform
Mar-06-19Upgrade Evercore ISI In-line → Outperform
Mar-05-19Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19Initiated UBS Neutral $87
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Mar-26-18Reiterated JMP Securities Mkt Outperform $169 → $207
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $205 → $200
Jan-08-18Reiterated B. Riley FBR, Inc. Buy $220 → $205
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Apr-02-20 05:50PM  Covid Report: Amgen Pops As Heavyweight Biotech Enters Coronavirus Ring Investor's Business Daily
07:00AM  Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19 Business Wire
Mar-31-20 02:18PM  8 Experimental Coronavirus Treatments to Watch Barrons.com
Mar-27-20 11:00AM  Big Pharma and Biotech Need to Do More in the Fight Against Covid-19 Barrons.com
Mar-26-20 01:04PM  Pfizer's Upjohn Combo With Mylan Is Delayed What That Means For PFE Stock Investor's Business Daily +8.53%
Mar-25-20 06:00AM  Alnylam Pharmaceuticals and Gen Sign Distribution Agreement in Turkey for ONPATTRO® (patisiran), the First-in-Class Gene-Silencing RNAi Therapeutic Business Wire
Mar-24-20 10:33AM  Biotechs brace for work losses, financing drop-off American City Business Journals
Mar-18-20 04:22PM  Were Hedge Funds Right About Piling Into Alnylam Pharmaceuticals (ALNY)? Insider Monkey
Mar-07-20 11:31AM  Why Is Alnylam (ALNY) Down 7% Since Last Earnings Report? Zacks
Mar-06-20 07:43AM  The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals Zacks
Mar-05-20 09:19AM  Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus Zacks
Mar-04-20 04:18PM  Alnylam Unveils Powerhouse Match-Up To Tackle Coronavirus Outbreak Investor's Business Daily +5.22%
02:52PM  Coronavirus update: 95,062 cases, 3,250 deaths; Starbucks shareholder meeting goes virtual MarketWatch
12:15PM  Alnylam unveils coronavirus drug plans: 'We've learned our lesson' from SARS American City Business Journals
12:12PM  Alnylam Unveils Powerhouse Match-Up To Tackle Coronavirus Outbreak Investor's Business Daily
09:55AM  Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More Zacks
09:22AM  Alnylam's Givlaari Gets Approval in Europe for Rare Disease Zacks
08:40AM  Vir Biotech, Alnylam Stitch COVID-19 Therapy Partnership Benzinga
08:04AM  Benzinga Pro's Top 5 Stocks To Watch For Wed., Mar. 4, 2020: JWN, VIR, CMG, AHPI, GNMK Benzinga
07:37AM  The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies Benzinga
07:27AM  Vir Biotechnology and Alnylam Pharma to collaborate on RNAi Therapeutics to treat coronavirus MarketWatch
07:00AM  Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19 Business Wire
Mar-03-20 07:00AM  Alnylam Announces Approval of GIVLAARI® (givosiran) in the European Union for the Treatment of Acute Hepatic Porphyria (AHP) in Adults and Adolescents Business Wire
Mar-01-20 07:22AM  3 Monster Growth Stocks That Can Climb Higher as Market Plunges TipRanks
07:07AM  Should You Be Pleased About The CEO Pay At Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Simply Wall St.
Feb-27-20 04:00PM  Alnylam Announces Changes to its Board of Directors Business Wire
Feb-26-20 08:00AM  Alnylam Announces Approval in Brazil of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy Business Wire
Feb-25-20 07:00AM  Alnylam to Webcast Presentations at Upcoming March Investor Conferences Business Wire
05:17AM  Here are the Mass.-based firms hit hardest in Monday's stock rout American City Business Journals
Feb-24-20 05:44AM  How biotech Alnylam plans to make a profit, and what stands in its way American City Business Journals -6.67%
Feb-20-20 08:00AM  Alnylam to Webcast Presentation at 9th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-18-20 07:00AM  Alnylam Completes Enrollment of HELIOS-A Phase 3 Study of Vutrisiran for the Treatment of hATTR Amyloidosis with Polyneuropathy Business Wire
Feb-11-20 05:54PM  Drug makers tap genetic test to save kids with seizures American City Business Journals
Feb-10-20 08:44PM  Edited Transcript of ALNY earnings conference call or presentation 6-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-07-20 09:25AM  Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat Zacks
Feb-06-20 08:00AM  Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity Business Wire
06:30AM  Alnylam Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-05-20 04:03PM  In the highest ranks of Mass. corporate leadership, women still scarce American City Business Journals
Jan-31-20 06:00AM  Alnylam Receives Positive CHMP Opinion for GIVLAARI (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents Business Wire
Jan-30-20 12:31PM  Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q4 Earnings Expected to Decline Zacks
Jan-29-20 12:02PM  Industry vet Holtzman steps down; Decibel retunes strategy American City Business Journals
Jan-28-20 10:39AM  Regeneron & Sanofi's sBLA for Dupixent Accepted by the FDA Zacks
Jan-27-20 04:00PM  Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results Business Wire
Jan-16-20 05:29AM  Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 46%? Simply Wall St.
Jan-15-20 05:39AM  Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure American City Business Journals
Jan-13-20 10:17AM  Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari Zacks
Jan-12-20 06:00PM  Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates Business Wire
Jan-10-20 04:00PM  Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) Business Wire
02:20PM  Cambridge startup raises $110M for re-doseable gene therapies American City Business Journals
07:00AM  Biogen signs neuro disease drug deal with Cambridge startup American City Business Journals
Jan-08-20 09:28AM  How Did Alnylam Pharmaceuticals, Inc. (ALNY) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Jan-07-20 08:40AM  These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen TipRanks
Jan-06-20 07:00AM  Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-01-20 07:40AM  We've made it to 2020. These are the top business issues to look for in the new year American City Business Journals
Dec-30-19 10:23AM  Alnylam Stock Up More Than 61% YTD on Pipeline Progress Zacks
09:35AM  Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now? Zacks
Dec-26-19 05:00AM  Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical. Barrons.com
Dec-24-19 07:30AM  10 Biotech M&A Targets Under The Scanner For 2020 Benzinga
Dec-18-19 08:50AM  Alnylam's Kidney Disease Drug Succeeds in Late Stage Study Zacks
Dec-17-19 04:12PM  Biotech Succeeds With Gene-Silencing Drug But Its Stock Rally Fails Investor's Business Daily
09:50AM  Alnylam's shares rise on late-stage rare disease results MarketWatch
07:00AM  Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 Business Wire
Dec-16-19 03:42PM  Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe Zacks
Dec-13-19 12:00PM  Here's Why Momentum Investors Will Love Alnylam Pharmaceuticals (ALNY) Zacks
12:00PM  Alnylam (ALNY) Moves to Buy: Rationale Behind the Upgrade Zacks
09:15AM  Guest Host Tonight Zacks
Dec-11-19 05:29AM  Sanofi to restructure Newton diabetes startup Onduo, saying it 'over-invested' American City Business Journals
Dec-04-19 05:31PM  Trade of the 2020's: Sell Gold, Buy Biotech Zacks
Dec-03-19 04:54PM  Alnylam Pharmaceuticals, Inc. (ALNY): These Hedge Funds Cashed Out Too Early Insider Monkey
Dec-02-19 08:12AM  Alnylam Pharmaceuticals (NASDAQ:ALNY) Is In A Strong Position To Grow Its Business Simply Wall St.
Nov-29-19 11:30AM  The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG Zacks
09:34AM  Alnylam Gets Second Product Approval Amid Stiff Competition Zacks
Nov-27-19 05:33PM  Why Gold is Headed to Zero -- And What You Should Buy Instead Zacks
Nov-26-19 09:39AM  Alnylam Pharmaceuticals, Inc. (ALNY) Shares March Higher, Can It Continue? Zacks +5.91%
08:00AM  Alnylam to Webcast Presentations at Upcoming December Investor Conferences TEST Business Wire Releases
08:00AM  Alnylam to Webcast Presentations at Upcoming December Investor Conferences Business Wire
Nov-25-19 09:42AM  The Medicines Company to be Acquired by Novartis for $9.7B Zacks +5.15%
08:37AM  Novartis Is Buying The Medicines Company for $9.7 Billion Barrons.com
Nov-22-19 07:00AM  Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day Business Wire
Nov-21-19 09:54AM  Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria Zacks
09:01AM  Alnylam (ALNY) Catches Eye: Stock Jumps 10.5% Zacks
07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-20-19 04:53PM  Alnylam shares jump on FDA approval MarketWatch +10.50%
02:21PM  Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI (givosiran) Business Wire
02:03PM  Alnylam Announces Approval of GIVLAARI (givosiran) by the U.S. Food and Drug Administration (FDA) Business Wire
01:22PM  UPDATE 2-Alnylam's rare genetic disorder drug priced at $575,000 per year Reuters
01:02PM  FDA gives early OK to Alnylam rare disease drug American City Business Journals
12:47PM  U.S. FDA approves Alnylam's drug for rare genetic disorder Reuters
08:41AM  Medicines Company Up on Rumors of Potential Buyout by Novartis Zacks
Nov-19-19 08:00AM  Alnylam Announces Second Annual Advocacy for Impact Grants Program Business Wire +5.61%
Nov-18-19 10:27AM  Medicines Company Posts Full Inclisiran Data From ASCVD Study Zacks
Nov-12-19 04:00PM  Alnylam to Webcast Presentation at Stifel 2019 Healthcare Conference Business Wire
Nov-09-19 12:00PM  Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study Business Wire
Nov-07-19 10:00AM  Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy? Zacks
Nov-06-19 09:00AM  Alnylam (ALNY) Upgraded to Buy: Here's Why Zacks
04:08AM  Edited Transcript of ALNY earnings conference call or presentation 31-Oct-19 12:30pm GMT Thomson Reuters StreetEvents
Nov-05-19 11:56AM  Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength Zacks
Nov-01-19 10:34AM  Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates Zacks
Oct-31-19 11:54AM  Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss Zacks
09:15AM  Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Tops Revenue Estimates Zacks
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARAGANORE JOHNChief Executive OfficerFeb 20Option Exercise9.1434,765317,752224,758Feb 21 04:02 PM
MARAGANORE JOHNChief Executive OfficerFeb 20Sale131.8534,7654,583,674189,993Feb 21 04:02 PM
SHARP PHILLIP ADirectorFeb 12Option Exercise12.4830,000374,400265,633Feb 13 04:06 PM
SHARP PHILLIP ADirectorFeb 12Sale130.0030,0003,900,000235,633Feb 13 04:06 PM
PAUL STEVEN MDirectorFeb 10Option Exercise14.6730,000440,10031,000Feb 11 04:08 PM
Greenstreet YvonneChief Operating OfficerFeb 10Option Exercise42.225,600236,43211,808Feb 11 04:08 PM
KEATING LAURIEEVP, Chief Legal OfficerFeb 10Option Exercise77.4010,000774,00022,258Feb 12 04:03 PM
Greenstreet YvonneChief Operating OfficerFeb 10Sale130.009,8921,285,9601,916Feb 11 04:08 PM
PAUL STEVEN MDirectorFeb 10Sale130.0030,0003,900,0001,000Feb 11 04:08 PM
KEATING LAURIEEVP, Chief Legal OfficerFeb 10Sale129.0010,0001,290,00012,258Feb 12 04:03 PM
Vaishnaw AkshayPresident, R&DFeb 07Option Exercise42.2222,750960,50534,923Feb 11 04:08 PM
Greenstreet YvonneChief Operating OfficerFeb 07Option Exercise42.226,250263,87512,458Feb 11 04:08 PM
Greenstreet YvonneChief Operating OfficerFeb 07Sale123.906,250774,3756,208Feb 11 04:08 PM
Vaishnaw AkshayPresident, R&DFeb 07Sale125.0023,7082,963,50011,215Feb 11 04:08 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 29Option Exercise77.406,337490,48414,932Jan 31 04:05 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 29Sale119.006,337754,1038,595Jan 31 04:05 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 27Option Exercise42.2234,3741,451,27049,632Jan 29 04:03 PM
KEATING LAURIEEVP, Chief Legal OfficerJan 27Sale117.7041,0374,829,9708,595Jan 29 04:03 PM
Fanucci MarshaDirectorNov 20Option Exercise13.8075,0001,035,00075,000Nov 22 04:06 PM
Greenstreet YvonneChief Operating OfficerNov 20Option Exercise42.228,404354,81710,320Nov 22 04:05 PM
Fanucci MarshaDirectorNov 20Sale100.0075,0007,500,0000Nov 22 04:06 PM
Greenstreet YvonneChief Operating OfficerNov 20Sale105.008,404882,4201,916Nov 22 04:05 PM
SHARP PHILLIP ADirectorNov 18Option Exercise16.4315,000246,450250,633Nov 20 04:17 PM
SHARP PHILLIP ADirectorNov 18Sale91.7115,0001,375,662235,633Nov 20 04:17 PM
Greene Barry EPresidentOct 22Option Exercise16.4358,913967,941111,851Oct 24 04:04 PM
Greene Barry EPresidentOct 22Sale89.9958,9135,301,58152,938Oct 24 04:04 PM
MARAGANORE JOHNChief Executive OfficerOct 14Option Exercise16.4349,456812,562239,449Oct 16 04:06 PM
MARAGANORE JOHNChief Executive OfficerOct 14Sale79.4549,4563,929,210189,993Oct 16 04:06 PM
MARAGANORE JOHNChief Executive OfficerMay 15Option Exercise16.4349,457812,579239,450May 17 04:07 PM
MARAGANORE JOHNChief Executive OfficerMay 15Sale70.0049,4573,461,990189,993May 17 04:07 PM
SHARP PHILIP ADirectorApr 15Option Exercise22.0915,000331,350250,633Apr 17 04:05 PM
SHARP PHILIP ADirectorApr 15Sale88.2315,0001,323,442235,633Apr 17 04:05 PM
open in yahoo | open in reuters | open in google